Statins enhance efficacy of venetoclax in blood cancers
J. Scott Lee(University of California, Irvine), Lee-or Herzog(University of California, Irvine), Dennis Juarez(University of California, Irvine), Richard J. Bellin(AbbVie (United States)), Susan O’Brien(University of California, Irvine), Anthony Letai(Dana-Farber Cancer Institute), Thanh-Trang T. Vo(University of California, Irvine), Lloyd T. Lam(National Institutes of Health), Shruti Bhatt(Dana-Farber Cancer Institute), Ahmed Hamed Salem(Ain Shams University), Angela G. Fleischman(University of California, Irvine), Matthew S. Davids(Dana-Farber Cancer Institute), Jonathan H. Schatz(University of Miami), Tu Xu(AbbVie (United States)), Sharmila Mallya(University of California, Irvine), Suresh Agarwal(Boston Medical Center), Andrew W. Roberts(AbbVie (United States)), Lingxiao Li(University of Miami), John R. Hanna(Dana-Farber Cancer Institute), Jia Jia(AbbVie (United States))
Cited by 86
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k